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Abstract CAD is a 1.5 MDa particle formed by hexameric association of a
250 kDa protein that carries the enzymatic activities for the first three steps in the de
novo biosynthesis of pyrimidine nucleotides: glutamine-dependent Carbamoyl
phosphate synthetase, Aspartate transcarbamoylase and Dihydroorotase. This
metabolic pathway is essential for cell growth and proliferation and is conserved in
all living organisms. However, the fusion of the first three enzymatic activities of
the pathway into a single multienzymatic protein only occurs in animals. In
prokaryotes, by contrast, these activities are encoded as distinct monofunctional
enzymes that function independently or by forming more or less transient com-
plexes. Whereas the structural information about these enzymes in bacteria is
abundant, the large size and instability of CAD has only allowed a fragmented
characterization of its structure. Here we retrace some of the most significant efforts
to decipher the architecture of CAD and to understand its catalytic and regulatory
mechanisms.
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The de Novo Biosynthetic Pathway for Pyrimidines
Nucleotides are essential compounds for all forms of life as building blocks for
RNA and DNA synthesis. Uracil, thymine and cytosine are the three major
pyrimidine bases for the formation of nucleic acids. These pyrimidines also exist as
free nucleotides (e.g. uridine 5-phosphate, UMP) or nucleosides (e.g. uridine) in
living tissues where they act as allosteric regulators or as coenzymes (Brown 1998).
In addition, uridine diphosphate (UDP) and cytidine diphosphate (CDP) play
prominent roles as activators and carriers of intermediate metabolites: UDP-glucose
is required for protein glycosylation and for the biosynthesis of polysaccharides
(e.g. glycogen, cellulose), and CDP-activated compounds (e.g. CDP-choline,
CDP-ethanolamine) are important intermediates for the biosynthesis of
phospholipids.
The cells require a constant supply of pyrimidines that can be obtained by two
different pathways (Fig. 17.1). Pyrimidines can be synthetized de novo from small
precursors such as ammonia, bicarbonate, ATP, aspartate (Asp) and
5-phosphoribosyl-1-pyrophosphate (PRPP) (Jones 1980). Alternatively, organisms
can employ different recycling or salvage pathways to uptake preformed pyrimidine
bases (uracil) or nucleosides (uridine) released during the turnover of nucleic acids or
acquired from the diet (Nyhan 2005). The relative contribution of de novo and salvage
pathways is dependent upon cell type and developmental stage (Evans andGuy 2004).
In general, fully differentiated and quiescent cells obtain pyrimidines through salvage
pathways and the de novo synthesis is low. Contrary, the de novo biosynthesis is
needed to fuel the high demand of pyrimidines during cell growth and proliferation.
The metabolic pathway leading to de novo synthesis of UMP consists of six
sequential enzymatic reactions that are preserved in all living organisms, from
microorganisms to humans (Jones 1980). Figure 17.1 depicts this process as an
assembly line, where the product of one enzyme acts as the substrate of the next,
and the semi-finished intermediates move somehow between active centers. The
metabolic pipeline starts with the manufacturing of carbamoyl phosphate (CP), a
labile and high-energy phosphate metabolite that is also a common precursor for the
de novo biosynthesis of arginine and urea (Jones 1980; Shi et al. 2018). CP is made
from bicarbonate, ammonia (obtained from glutamine hydrolysis) and two mole-
cules of ATP, in a four-step reaction catalyzed by carbamoyl phosphate synthetase
(CPS; EC 6.3.5.5), an enzyme actually composed of two activities, a
glutamine-dependent amidotransferase (GLN) and a synthetase (SYN) (Meister
1989; Simmer et al. 1990). In a second step, CP and Asp are used by the enzyme
aspartate transcarbamoylase (ATC; EC 2.1.3.2) to form carbamoyl aspartate. Next,
the enzyme dihydroorotase (DHO; EC 3.5.2.3) catalyzes the condensation of car-
bamoyl aspartate to dihydroorotate, the first cyclic compound of the pathway.
Dihydroorotate is further oxidized to orotate by dihydroorotate dehydrogenase
(DHODH; EC 1.3.5.2), an enzyme that in eukaryotes is tethered to the outer face of
the inner mitochondrial membrane and couples pyrimidine synthesis to the respi-
ratory chain (Fig. 17.1). Orotate is a completed pyrimidine base and is incorporated
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to the activated sugar PRPP by the enzyme orotate phosphoribosyltransferase
(OPRT; EC 2.4.2.10), producing the nucleotide orotidine 5-phosphate (OMP).
Lastly, the OMP decarboxylase (OMPDC; EC 4.1.1.23) converts OMP to UMP,
which is subsequently phosphorylated to UDP and UTP by different kinase activ-
ities. It is from these nucleotides that the other common pyrimidine derivatives arise
(Fig. 17.1).
Fig. 17.1 Schematic outline of de novo and salvage pathways for pyrimidine biosynthesis in
animals. The reactions catalyzed by the cytosolic multienzymatic proteins CAD and UMPS are
framed in grey background, while the intermediate step occurs in the mitochondria. The salvage
pathways for recycling of uracil or uridine are indicated in blue background. The numerous
reactions that transform UMP into the pool of different pyrimidine nucleotides are represented in
brownish background, with final fates for the different nucleotides shown in pink
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Although the six enzymatic steps for de novo manufacturing of UMP are evo-
lutionary conserved, the organization of the enzymatic activities varies greatly in
prokaryotes, protists, plants, fungi, and animals (Fig. 17.2a). In most prokaryotes
and plants, the first three reactions are catalyzed by distinct enzymes that work
independently or by forming more or less transient complexes (Jones 1980; Zrenner
et al. 2006). In these organisms a single CPS, formed by association of two distinct
proteins with GLN and SYN activities, makes CP both for the synthesis of
pyrimidine and arginine, and thus, ATC becomes the first committed enzyme for de
novo pyrimidine synthesis. In some bacteria, like Escherichia coli, ATC is under a
strict allosteric control, being feedback inhibited by the pyrimidine nucleotides UTP
and CTP and activated by a purine nucleotide, ATP [reviewed in (Allewell 1989;
Jacobson and Stark 1973)]. The enzyme is formed by two trimers of catalytic
subunits related by three dimers of regulatory subunits where nucleotide effectors
bind, inducing large conformational changes in the holoenzyme [reviewed in
(Lipscomb 1994)] (Fig. 17.2b). In other bacteria, ATC is not regulated and consists
of a catalytic trimer without regulatory subunits that functions independently or
forming a non-covalent complex with DHO (Fig. 17.2c).
The scenario is more puzzling in other organisms, where the enzymatic activities
appear highly organized. Early studies indicated that in simple eukaryotes, such as
Neurospora or Saccharomyces, two CPSs provide distinct intracellular CP pools for
pyrimidine and arginine synthesis (Fig. 17.2a). The arginine-specific CPS, formed
like in bacteria by the non-covalent association of two proteins with GLN and SYN
activities, locates in the mitochondria (Lacroute et al. 1965), whereas the
pyrimidine-specific CPS and ATC activities are present in a single bi-functional
protein encoded by the genes pyr-3 in Neurospora (Williams et al. 1970; Williams
and Davis 1970) or ura2 in S. cerevisiae (Lue and Kaplan 1969). This bi-functional
protein also contains an inactive DHO-like domain, and these organisms have a
monofunctional DHO enzyme encoded by an independent gene (ura4 in S. cere-
visiae) (Denis-Duphil 1989; Souciet et al. 1989) (Fig. 17.2a). Thus, in fungi only
five genes code for the six enzymatic activities for UMP synthesis.
Similarly, in animals, distinct mitochondrial and cytosolic CPSs make CP pools
for arginine and pyrimidine synthesis, respectively (Jones 1980) (Fig. 17.2a). In
most terrestrial vertebrates, there is an arginine-specific CPS (CPS-1; EC. 6.3.4.16)
formed by the fusion of an inactive GLN domain and a SYN domain, which is only
expressed in the mitochondria of hepatocytes and requires acetylglutamate as a
co-factor (Jones 1980; Rubio et al. 1981). CPS-1 cannot hydrolyze glutamine and is
used to detoxify free-ammonia directly through the urea cycle. On the other hand,
early studies proved the existence of a pyrimidine-specific CPS (CPS-2) that
co-purified with the ATC activity in some sort of cytosolic complex (Hoogenraad
et al. 1971).1 Unlike in fungi, this complex also contained DHO activity (Shoaf and
1There is yet a CPS-3 in some invertebrates and fish that combines properties of CPS-1 and CPS-2
[Anderson PM (1989) Biochem J 261(2): 523–529]. It consists of a single polypeptide with GLN
and SYN domains, requires acetylglutamate as co-factor, is not regulated by nucleotides and
hydrolyzes glutamine.
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Fig. 17.2 Organization of the enzymes involved in de novo pyrimidine biosynthesis. a Schematic
representation of the six enzymatic activities needed for de novo pyrimidine biosynthesis of UMP
in eubacteria, fungi and animals. The rectangles represent individual proteins or domains within
multienzymatic proteins. A second arginine-specific CPS present in the mitochondria of fungi and
some animals is also shown. b, c Space filling representation of the ATC and DHO enzymes in
Escherichia coli (b) and Aquifex aeolicus (c). E. coli ATC is an holoenzyme formed by two trimers
of catalytic subunits related by three dimers of regulatory subunits. The enzyme undergoes
conformational transitions between active (R) and inactive (T) states regulated by the binding of
substrates, inhibitors and allosteric effectors. In A. aeolicus, ATC and DHO enzymes are intimately
associated forming a heterododecamer
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Jones 1971), leading M. E. Jones to postulate that the initial three enzymes for the
de novo biosynthesis in mammals could form a stable complex or be part of a single
multienzymatic protein. This association was named CAD for the first letters of the
distinct enzymatic activities, and was subsequently found in every animal species
investigated, from Dictyostelium to human [reviewed in (Evans 1986; Jones 1980)].
The nature of this multienzymatic association was not unveiled until it was
purified to homogeneity by the group of G. Stark from hamster cells treated with the
drug PALA (N-phosphonacetyl-L-aspartate). PALA was synthetized as a potent
inhibitor of E. coli ATC that combines features of both enzyme substrates (CP and
Asp) and was postulated to mimic the transition state of the reaction (Collins and
Stark 1971). PALA was also effective in inhibiting the growth of mouse tumors,
proving that de novo pyrimidine synthesis is required for cell proliferation (Swyryd
et al. 1974; Yoshida et al. 1974). However, some of the cells developed resistance
to the inhibitory effect of PALA by producing more than 100 times the original
activity of the three-enzyme complex (Kempe et al. 1976). When the complex was
isolated from these overproducing cells, the three catalytic activities were found
integrated within a single polypeptide of *250 kDa that self-associated in a
mixture of oligomeric forms, mostly trimers and hexamers (Coleman et al. 1977;
Kempe et al. 1976). This physical association between the three enzymes was
confirmed by a combined genetic, biochemical and immunological approach using
CAD defective mutants in CHO cells (Davidson and Patterson 1979).
The attempts to purify CAD revealed its extraordinary susceptibility to prote-
olytic cleavage, which allowed the isolation of different protein fragments retaining
different enzymatic activities (Davidson et al. 1981; Evans 1986; Kim et al. 1992;
Mally et al. 1981). The analysis of the proteolytic fragments and of mutants in the
CAD locus in Drosophila (rudimentary gene) provided strong evidence of a simple
domain structure, where enzymatic activities were present in CAD as different
functional domains connected by more or less unstructured linker regions. The
correct order of the domains, GLN-SYN-DHO-ATC (Fig. 17.2a), was not con-
firmed until the genes from different organisms were fully sequenced [Drosophila
(Freund and Jarry 1987); hamster (Shigesada et al. 1985); human (Davidson et al.
1990); Dictiostelyum (Faure et al. 1989); and S. cerevisiae ura2 (Denis-Duphil
1989; Souciet et al. 1989)].
In addition, a number of gene dissection experiments proved that fragments of
CAD could complement E. coli deficient in CPS, DHO or ATC activities, indi-
cating that the isolated enzymatic CAD domains were functional and topologically
independent [reviewed in (Davidson et al. 1993)].
CAD is not the only multienzymatic protein in the de novo pyrimidine pathway.
In animals (and also in plants), the OPRT and OMPDC activities, are also fused
into a single bi-functional protein named UMP synthetase (UMPS) (Fig. 17.2a)
(Jones 1980; Traut and Jones 1979). Thus, two cytosolic multienzymatic proteins
are responsible for catalyzing five out of six steps in UMP synthesis in animals
(Jones 1980; Shoaf and Jones 1971), while the reaction catalyzed by the dehy-
drogenase occurs inside the mitochondria (Fig. 17.1).
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The evolutionary diversity shown in Fig. 17.2a is difficult to reconcile with the
view of a metabolic assembly line formed by enzymes functioning as autonomous
catalytic units. Enzymes work more efficiently when assembled into complexes that
favor the communication, coordination and interdependence of the different
activities and have the potential to express unique catalytic and regulatory prop-
erties (Gaertner 1978). Likely, the most effective of these interactions is the
covalent linkage into a multienzymatic conjugate such as CAD. We are familiar
with the dynamics that improve the relation with co-workers in our everyday life at
the laboratory or in the office. Now, we want to understand whether and how
enzymes apply similar teamwork strategies to make pyrimidines in the most effi-
cient manner.
Although bacterial CPS, ATC and DHO enzymes are well characterized both
structurally and biochemically, the large size of CAD and the high sensitivity to
proteases hampered many structural characterization attempts so far. In this chapter,
we retrace some of the most significant efforts to decipher the structure of CAD and
to understand its functioning.
Starting from the Beginning: The GLN and SYN Domains
CP is a small and highly unstable molecule that requires a truly remarkable protein
machinery of more than one thousand aminoacids for its synthesis. The reaction
involves three discrete chemical steps with canalization of highly reactive and
unstable intermediates: carboxyphosphate, ammonia and carbamate (Anderson and
Meister 1965; Meister 1989) (Fig. 17.3a). In a first step, a molecule of bicarbonate
is phosphorylated at the expense of one ATP molecule to form carboxyphosphate
and ADP. Then, a molecule of ammonia obtained directly (urea cycle CPS-1) or
hydrolyzed from glutamine reacts with the carboxyphosphate to form carbamate
and inorganic phosphate. In a final step, carbamate is phosphorylated by consuming
a second ATP molecule to form CP.
All known CPSs share a common reaction mechanism, and present substantial
sequence homology and similar multidomain architecture. As previously men-
tioned, CPS is composed of two parts, a *40 kDa GLN that delivers ammonia and
a *120 kDa SYN that catalyzes the three-step reaction mentioned above.
The GLN and SYN parts exist either as different subunits, such as in bacterial CPSs
or in the arginine-specific CPS in fungi, or they are connected by a short linker
within a single polypeptide, such as in the urea-cycle CPS-1 (Fig. 17.2a).
Alternatively, GLN and SYN can be fused together with ATC and DHO (or an
inactive DHO-like domain) forming the CAD (or CAD-like) multienzymatic pro-
tein. Currently, only the structures of the CPS from E. coli and the
ammonia-dependent CPS-1 from human hepatocytes have been characterized.
E. coli CPS has been extensively studied both biochemically and structurally
(Holden et al. 1998; Meister 1989; Raushel et al. 1998; Thoden et al. 1998, 1999a,
b, c, d, 2002, 2004). The enzyme is a stable heterodimer formed by the small GLN
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Fig. 17.3 E. coli CPS structure. a Schematic representation of the small and large subunits of
E. coli CPS and partial reactions catalyzed by each domain within the protein. The binding of
allosteric effectors to the C-terminal region of the protein is indicated. b Cartoon representation
of the enzyme heterodimer, with domains colored as in (a). Glutamine (GLN), AMPPNP
(a non-hydrolyzable analog of ATP), UMP and ornithine (ORN) are represented as spheres. The
internal tunnel connecting the three active sites is represented as cyan mesh. c Space filling
representation of E. coli CPS tetramer as found in the crystal structure. d Superposition of the
carboxyphosphate synthetic component (L1; shown in yellow) and the carbamoyl phosphate
synthetic component (L3; orange) with AMPPNP represented as spheres. The A, B and C lobes
forming the ATP-grasp fold are indicated
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subunit and the large SYN subunit (Fig. 17.3a), encoded respectively by the genes
carA and carB. The large subunit, also holds the binding sites for the allosteric
regulators. Although the GLN/SYN heterodimer is the functional unit of E. coli
CPS, the protein readily converts to a dimer or a tetramer with unaffected catalytic
properties (Anderson 1986) (Fig. 17.3c).
CPS-1, on the other hand, is a protein of 1500 amino acids divided into an
inactive N-terminal GLN domain and a C-terminal SYN domain, which correspond
respectively, to the small and large subunits of bacterial CPS (Fig. 17.4a). The
structure of human CPS-1 probed to be highly similar to that of E. coli CPS (de Cima
et al. 2015), as correctly inferred from biochemical studies (Nyunoya et al. 1985;
Powers-Lee and Corina 1986). Despite being inactive, the GLN domain is an
integral part of the enzyme and is tightly associated with the SYN domain.
Fig. 17.4 Human CPS-1 structure. a Schematic representation of the enzyme with the partial
reactions catalyzed by each protein region. The allosteric activation by binding of acetylglutamate
(NAG) to the C-terminal region is indicated. b Space filling representation of CPS-1 dimer as seen
in the asymmetric unit of the crystal. c, d Cartoon representation of human CPS-1 free (c) or bound
(d) to NAG. Binding of NAG induces conformational changes that define the path of the tunnel -
shown in red surface- through the active sites. The N- and C-terminal moieties of the protein are
connected by a 20 aa linker that spans 50 Å and appears partially disordered in the structure free of
acetylglutamate (indicated by a dashed line)
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In solution, CPS-1 exists in a monomer-dimer rapid equilibrium where the monomer
predominates (Diez-Fernandez et al. 2013; Pierson and Brien 1980; Rubio et al.
1981) (Fig. 17.4b). Both the monomers and dimers are active upon acetylglutamate
binding (Lusty 1981), and there is no evidence of formation of tetramers.
So far, there is no direct structural information about the GLN or SYN domains
of CAD. The CPS-2 activity of CAD is of outmost importance since it is the
rate-limiting reaction in the biosynthesis of pyrimidines and the point for allosteric
control (Coleman et al. 1977; Mori and Tatibana 1978). The difficulty to produce a
stable construct for these regions of the protein has precluded many crystallization
attempts so far. Nevertheless, the CPS-2 activity of CAD is expected to share
similar structural features with E. coli CPS and with human CPS-1. The comparison
between the structures of these evolutionary distant enzymes should give us some
hints on the structure and functioning of CAD.
GLN Domain
The small subunit of E. coli CPS and the N-terminal moiety of human CPS-1
exhibit a globular shape divided into two lobes (Figs. 17.3 and 17.4). The
N-terminal lobe of *16 kDa (named S1) is formed by four major a-helices and
two perpendicular four stranded b-sheets. The C-terminal lobe of *25 kDa (S2)
presents a central b-sheet of ten elements flanked on both sides by six a-helices,
which is characteristic of the class I family of amidotransferases (Nyunoya and
Lusty 1984). These glutaminases share a common reaction mechanism that involves
the formation of a glutamyl-thioester intermediate between glutamine and a cat-
alytic Cys. A conserved His is also important to activate the Cys for nucleophilic
attack. In E. coli CPS, the catalytic residues, C269 and H353, locate at the S2 lobe,
and the active site is formed at the interface with the S1 lobe (Figs. 17.3b and
17.5a). The reaction process has been delineated by different crystal structures of
E. coli CPS bound to various ligands and bearing different mutations (Thoden et al.
1997, 1998, 1999a, c, d, 2002, 2004), and the formation of the glutamyl-thioester
intermediate has been demonstrated biochemically both for E. coli CPS and for
CAD (Chaparian and Evans 1991; Wellner et al. 1973). In contrast, human CPS-1
presents a Ser residue (S294) replacing the catalytic Cys (Fig. 17.5a), explaining
why this domain is inactive.
The GLN domain of CAD is expected to be structurally similar to the GLN
moieties of E. coli CPS and CPS-1. Sequence alignment shows the preservation of
the secondary structural elements throughout the predicted S1 and S2 lobes and the
conservation of active site residues, including the catalytic Cys and His residues
(C252 and H336 in human CAD) (Figs. 17.5a and 17.6). Interestingly, the isolated
GLN domain of hamster CAD has been produced recombinantly in bacteria but is
only active when mixed in stoichiometric amounts with the large subunit of E. coli
CPS, supporting a high degree of conservation between both enzymes (Guy and
Evans 1994). It is expected that, similarly to E. coli CPS and human CPS-1, both
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Fig. 17.5 Structural
conservation between CPSs.
a Cartoon representation of
the superposition of the active
site of E. coli CPS small
subunit (blue) with the
equivalent region in human
CPS-1 (pink). A molecule of
glutamine (GLN) bound to
the E. coli enzyme is shown
in yellow sticks and the
interactions with conserved
residues are indicated by
dashed lines. b Similar
representation for the
superposition of the active
sites of the carboxyphosphate
synthetic component of
E. coli and human CPSs.
A molecule of ADP and an
inorganic phosphate present
in both structures are shown
as green sticks. Potassium and
divalent metal ions (Mg2+ in
human CPS-1 or Mn2+ in
E. coli CPS) are shown as
spheres. c Allosteric domain
of E. coli CPS showing the
overlapping binding sites for
UMP and IMP. At high
concentrations, ornithine
(ORN) and a molecule of
inorganic phosphate (Pi) can
also bind at this position.
d Allosteric domain in human
CPS-1 with acetylglutamate.
In a, b and d, the numbers of
the conserved residues in
human CAD are indicated in
parentheses
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the S1 and S2 participate in an extensive interaction with the SYN domain in CAD
(Figs. 17.3b and 17.4c). This interaction, which stabilizes both subunits in E. coli
CPS (Cervera et al. 1993), somehow ensures the synchronization and enhancement
of the GLN and SYN activities both in E. coli CPS and in CAD, likely to avoid
wasteful hydrolysis of glutamine or ATP if the other substrates of the reaction are
not available (Hewagama et al. 1999; Miles et al. 1998; Miles and Raushel 2000;
Miran et al. 1991).
SYN Domain
The large subunit of E. coli CPS and the C-terminal moiety of CPS-1 are divided
into four structural units (L1–4; Figs. 17.3a and 17.4a). L1 and L3 correspond to
two homologous phosphorylation domains (Britton et al. 1979) that share 40%
sequence identity and probably arose by a gene duplication and fusion event
(Nyunoya and Lusty 1983). These two synthetic components form a
pseudo-homodimer with nearly exact twofold rotational symmetry and are topo-
logically equivalent but not identical, as expected based on their different substrates
and interactions with the rest of the protein (Figs. 17.3b, d and 17.4c) (Thoden et al.
1997). L1 is the carboxyphosphate synthetic component responsible for the phos-
phorylation of bicarbonate and is in contact with the GLN domain. L3 is the CP
component that phosphorylates carbamate and interacts with the allosteric region
(L4) described below. Both synthetic components are structured in an “ATP-grasp”
fold, with three lobes surrounding (“grasping”) the nucleotide (Fawaz et al. 2011)
(Fig. 17.3d). The A lobe (E. coli CPS L1 residues 1–140 and L3 residues 554–686)
exhibits a modified Rossmann-fold with a five stranded b-sheet flanked on both
sides by a-helices. The B lobe (E. coli CPS L1 residues 141–210 and L3 residues
687–756) folds in a four-stranded antiparallel b-sheet flanked on the solvent side by
two a-helices. The C lobe (E. coli L1 residues 211–403 and L3 residues 757–936)
is nucleated by an antiparallel b-sheet flanked by four helical regions. The active
site, located between the B- and C-lobes, is highly similar in E. coli CPS and human
CPS-1 (Fig. 17.5b). The nucleotide, interacting residues and divalent cations
occupy virtually identical positions in both enzymes. Even the potassium ions,
which are known to be required for the activity (Anderson and Meister 1966)
occupy similar positions at the active sites.
JFig. 17.6 Sequence alignments. Multiple alignment of the CPS-2 in human CAD, human CPS-1
and E. coli CPS sequences. A schematic diagram of the protein domains is shown on the left side.
The red or blue backgrounds indicate respectively the a-helices and b-strands observed in the
crystal structures or predicted from the CAD sequence. Residues involved in binding of glutamine,
in the L1 or L3 phosphorylation sites and in the binding of allosteric effectors are highlighted in
yellow, green and orange background, respectively. The N-terminal end of human CPS-1
corresponds to a mitochondrial targeting peptide that is cleaved off from the mature protein and is
not included in the alignment
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The synthetic L1 and L3 domains are linked by the L2 domain, composed of
seven a-helices and a two stranded b-sheet. In E. coli CPS, L2 participates in the
formation of the tetramers, and thus it was named as the oligomerization domain
(Thoden et al. 1997) (Fig. 17.3b, c). The interaction between two oligomerization
domains is relatively small, as expected from the readily conversion between
monomer and tetramer (Anderson 1986). In CPS-1, L2 is not involved in
oligomerization and received the name of the integrating domain, for its role in
embracing L1 and connecting the L1 and L3 with the GLN moiety (Fig. 17.4) (de
Cima et al. 2015).
Based on the alignment of Fig. 17.6, the predicted synthetic L1 and L3 domains
and the connecting L2 domain of CAD are expected to be highly similar to E. coli
CPS and CPS-1, including the conserved catalytic residues at the phosphorylation
sites (Figs. 17.5b and 17.6).
Allosteric Regulation
Most CPSs are under a strict allosteric control. Pyrimidine-specific CPSs are gen-
erally activated by the purine nucleotide inosine 5′-monophosphate (IMP) or by
PRPP, a substrate for both purine and pyrimidine synthesis, and are feedback
inhibited by UMP or UTP, the products of de novo pyrimidine synthesis (Jones
1980), whereas arginine-specific CPSs are generally activated by ornithine, a
substrate with CP for the synthesis of arginine. CPS-1, on the other hand, is
essentially an inactive enzyme that requires the activation by the co-factor acetyl-
glutamate (Rubio et al. 1983).
E. coli CPS makes CP both for the synthesis of arginine and pyrimidines, and
thus, it is inhibited by UMP and is activated by IMP and ornithine (Fig. 17.3a)
(Meister 1989). These allosteric effectors regulate the activity primarily by raising
or lowering the KM for ATP nearly 10-fold (Braxton et al. 1992, 1996).
Biochemical and structural studies have proven that UMP, IMP and ornithine bind
at the *20 kDa C-terminal region of the large subunit, the L4 domain (Fig. 17.3a)
(Cervera et al. 1996; Czerwinski et al. 1995; Rubio et al. 1991; Thoden et al.
1999c). This allosteric domain is structured in a Rossmann-fold (nearly identical to
the A lobe in the L1 and L3 synthetic components) with a five-stranded parallel
b-sheet flanked on either side by a-helices (Fig. 17.3b). UMP and IMP compete for
binding in a nearly identical position at the carboxy-edge of the central b-sheet
(Fig. 17.5c) (Bueso et al. 1999; Cervera et al. 1996; Mora et al. 1999; Thoden et al.
2004; Thoden et al. 1999c). Ornithine on the other hand, binds in a different pocket,
12 Å apart from the nucleotide binding site, at the interface between the allosteric
domain and the CP synthetic domain (Fig. 17.3b) (Thoden et al. 1997). Some
crystal structures show a second molecule of ornithine (and a phosphate ion) at the
UMP/IMP binding site, likely due to the high concentrations of these ligands used
in the crystallization solution (Fig. 17.5c).
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Acetylglutamate also binds to the L4 domain of CPS-1 (Figs. 17.4d and 17.5d)
(de Cima et al. 2015; Rodriguez-Aparicio et al. 1989). Despite having very different
effector molecules, the CPS-1 and E. coli CPS allosteric domains are structurally
very similar. Indeed, acetylglutamate occupies the equivalent position of UMP/IMP
in E. coli CPS, and interacts with similar conserved elements (Fig. 17.5c, d).
The CPS-2 activity of CAD is allosterically inhibited by UTP and activated by
PRPP, which alter the apparent KM for ATP (Mori and Tatibana 1978). The binding
of the allosteric effectors is also expected to occur at a regulatory domain at the
C-terminal region of the SYN domain. This is supported by analogy to other CPSs
(Rubio 1994) and because the UTP inhibition is lost when this region is deleted
(Liu et al. 1994). Furthermore, E. Carrey discovered that the UTP inhibition is
abolished upon phosphorylation by cAMP-dependent protein kinase A (PKA) of
residue S1406 at the predicted allosteric domain (Carrey et al. 1985; Carrey and
Hardie 1988). Based on sequence conservation and preservation of secondary
structural elements, it is likely that the L4 domain of CPS-2 will exhibit the fold
observed in E. coli CPS and human CPS-1. We propose that residue S1406 will
occupy the equivalent position of T1443 in CPS-1, which directly binds to
acetylglutamate (Figs. 17.5d and 17.6). Thus, it is feasible that a phosphorylation at
residue S1406 in CAD would pose a steric impediment for the binding of UTP, as
originally postulated by Carrey (Carrey 1995a).
CAD is also phosphorylated at residue T456 within the L1 domain via the MAP
kinase (Erk1/2) signaling cascade (Graves et al. 2000). This modification converts
UTP from an inhibitor to a modest activator and stimulates the activation by
PRPP. The expected similarity with other CPSs suggests that this residue is far from
the allosteric domain and thus, it is difficult to adventure a possible mechanism that
explains the effect of the modification on the binding of the allosteric effectors or in
the modulation of the activity.
So far, we focused the attention on CAD and ignore the comparison with the
CAD-like protein from fungi. Although not shown in the alignment of Fig. 17.6,
the GLN and SYN domains of CAD-like proteins are predicted to share the overall
structure with other CPSs. In particular, S. cerevisiae URA2 has a unique binding
site for UTP, likely localized at the putative L4 allosteric domain, which regulates
both CPS and ATC activities (Antonelli et al. 1998), and at least in vitro, does not
appear to be phosphorylated by PKA (Denis-Duphil et al. 1990). Thus, the regu-
latory domain appears to be conserved in all CPSs, including some that do not
respond to allosteric effectors. Indeed, the unregulated arginine-specific CPS in S.
cerevisiae (Fig. 17.2a) holds a latent allosteric domain that binds UMP and IMP,
although the nucleotides do not seem to have any effect on the activity of the
protein (Eroglu and Powers-Lee 2002).
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A Reaction Tunnel
The E. coli CPS structure revealed an exceptional feature: the GLN active site is 45
Å away from the bicarbonate phosphorylation site, and this one is 35 Å apart from
the phosphorylation site for carbamate (Thoden et al. 1997). Thus, the unstable
reaction intermediates must be shuttled between the active centers without exposure
to the bulk solvent. In E. coli CPS, a narrow tunnel, more than 90 Å long, runs
through the interior of the protein, connecting all three active sites (Fig. 17.3b). The
extensive interaction between the small subunit and the first half of the large subunit
provide a safe pathway for the delivery of ammonia to the L1 active site where it
will react with carboxyphosphate to form carbamate. This “ammonia” tunnel is
lined by non-reactive residues that can form H-bonds with ammonia. The second
portion of the tunnel transports carbamate from the L1 to the L3 active sites where it
is phosphorylated to CP. This “carbamate” tunnel passes across the twofold rota-
tional axis between the two synthetic domains and is delimited by few charged side
chains to prevent the reaction with carbamate.
In human CPS-1, many of the residues that in E. coli CPS line the ammonia
channel are conserved, but the Gly at the exit of the channel at the interface between
the GLN and SYN domains is replaced by a Gln (Q318) that blocks the path (de
Cima et al. 2015). This blockage explains why some CPS-1 enzymes have a
complete GLN active site (e.g. CPS-1 from Rana catesbiana), including the cat-
alytic Cys and His residues, but are still unable to deliver the ammonia hydrolyzed
from glutamine to the SYN domain (Saeed-Kothe and Powers-Lee 2003) (de Cima
et al. 2015). Likely in CPS-1, ammonia intake follows a different path to that
delineated in E. coli CPS. It has been proposed that this alternative entry could also
exist in other CPSs, including CAD, since they are active with external ammonia
although at high concentrations (de Cima et al. 2015).
In E. coli CPS, the intramolecular tunnel is formed even in the absence of a full
set of substrates. This could be due to the fact that the protein is always crystallized
in presence of the allosteric activator, ornithine. In turn, the structures of human
CPS-1 free or bound to acetylglutamate show important differences in the tunnel
that explain in part the mechanism of activation by the co-factor (Fig. 17.4c, d).
Binding of acetylglutamate causes small changes in the allosteric domain that are
propagated to the L3 domain through the movement of a potassium binding loop
also present in E. coli CPS (de Cima et al. 2015). This movement induces
long-range conformational changes that stabilize the two phosphorylation sites and
promote the correct formation of the reaction tunnel (de Cima et al. 2015). Similar
changes triggered by the allosteric effectors are expected to occur both in E. coli
CPS and in the SYN domain of CAD.
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A Cooperative ATC Domain
The arrangement of the domains along the CAD polypeptide does not follow the
order of the reactions in de novo pathway (Fig. 17.2a). The ATC domain, located at
the C-end of the protein, catalyzes the second step after CPS, the transfer of the
carbamoyl group of CP to the a-amino group of aspartate (Asp) to form carbamoyl
aspartate (Figs. 17.1 and 17.2a) (Jones 1980).
ATC is likely one of best characterized enzymes ever. In particular, the amount
of biochemical and structural information obtained on E. coli ATC is impressive,
becoming a text-book enzyme and, together with hemoglobin, a paradigm of
protein cooperativity and allosteric regulation [reviewed in (Allewell 1989;
Jacobson and Stark 1973; Lipscomb 1994)]. E. coli ATC consists of twelve
polypeptides chains: six catalytic chains of 33 kDa organized as two catalytic
trimers, and six regulatory chains of 17 kDa forming three regulatory dimers
(Fig. 17.2b). The affinity for the substrates is regulated both by the binding of
substrates to other active sites (homotropic effects) and by the binding of nucleotide
effectors to the regulatory subunits (heterotropic effects). This regulation requires
the communication of conformational changes between chains and subunits
(Schachman 1988). Indeed, the dissociation of the holoenzyme results in isolated
catalytic trimers that are more active but lack cooperativity and allosteric regulation
(Gerhart and Holoubek 1967). Numerous crystal structures of E. coli ATC,
including the active (R) and inactive (T) states of the holoenzyme (Fig. 17.2b), and
the unregulated catalytic trimer, helped to unveil the complexity of the catalytic and
regulatory mechanisms (Lipscomb and Kantrowitz 2011). There are also crystal
structures for other forms of ATC found in bacteria, such as the non-regulated
catalytic trimers of Bacillus subtilis or the DHO-associated ATC from Aquifex
aeolicus (Fig. 17.2c) (Stevens et al. 1991; Zhang et al. 2009). However, until
recently, there were no structures of any eukaryotic ATC.
The ATC domain of human CAD was the first eukaryotic ATC to be structurally
characterized (Ruiz-Ramos et al. 2013, 2016). As predicted (Scully and Evans
1991), the domain shows high similarity with the catalytic subunits of bacterial
ATCs. The enzyme is a homotrimer with equilateral triangular appearance, and
three active sites located in between subunits (Fig. 17.7a). Each subunit is divided
in an N-terminal domain and a C-terminal domain of similar size, both structured by
a central b-sheet of five parallel strands flanked by a-helices (Fig. 17.7b). The
active site locates at the cleft between the N- and C-domains with participation of a
loop (CP-loop) from the adjacent subunit. The N-terminal domain provides most of
the contacts with the other subunits and holds the binding site for CP, whereas the
C-domain occupies an external position at the trimer and provides the binding site
for Asp. There are two mobile loops, the CP-loop at the N-domain (named loop 80s
in E. coli ATC) and the Asp-loop at the C-domain (loop 200s in E. coli ATC) that
appear flexibly disordered in the absence of substrates (Fig. 17.7b).
ATC catalyzes an ordered reaction, with CP binding before Asp, and carbamoyl
aspartate leaving before phosphate (Collins and Stark 1969; Porter et al. 1969). CP
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binding at the N-domain induces the positioning of the CP-loop from the adjacent
subunit at the active site, and promotes a partial hinge-closure of the C-domain.
These conformational changes favor the binding of Asp to a contiguous pocket in
the active site. Binding of both substrates induces a further approximation between
the N- and C-domains and a rigid body rotation of the Asp-loop that closes the
active site (Fig. 17.7b). Overall, these movements are proposed to compress the
substrates and favor the reaction (Collins and Stark 1969; Ruiz-Ramos et al. 2016).
Fig. 17.7 ATC domain of human CAD. a Space filling representation of the trimer formed by the
isolated ATC domain of human CAD in two perpendicular orientations. Each subunit is
represented in a different color. b Cartoon representation of human ATC subunit, with the N- and
C-domains represented in blue and green, respectively, and the Asp-loop depicted in purple. The
arrows indicate the closure movement of the subunit upon PALA binding. PALA is shown in
spheres, with the CP and the Asp moieties colored in yellow and red, respectively. The CP-loop
from the adjacent subunit is depicted in red. c Detail of the interactions between PALA and
residues at the active site
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The active sites of human and E. coli ATCs are indistinguishable, confirming a
common reaction mechanism for both enzymes (Collins and Stark 1969; Gouaux
et al. 1987; Ruiz-Ramos et al. 2016). Catalysis occurs by nucleophilic attack of the
amino nitrogen of Asp on the amide carbon of CP. The phosphate group of CP or
the side chain of residue H2052 (H134 in E. coli ATC) are likely candidates to act
as general base, deprotonating and increasing the nucleophilicity of the a-amino
group of aspartate, whereas the positive dipole of the nearby a-helix and the side
chains of residues R2024 (R105) and H2052 (H134) act in concert to polarize the
carbonyl group of CP and to stabilize the transition state of the reaction
(Fig. 17.7c).
Figure 17.7c shows how every polar atom of PALA interacts with the protein,
explaining the nanomolar affinity for the inhibitor (Newell et al. 1989; Ruiz-Ramos
et al. 2016). The dissociation of PALA from this highly stable complex is
impossible without reversing all the conformational changes, and this is a slow
process that explains why the molecule acts as a nearly irreversible inhibitor. An
unexpected fact is that PALA binds to human ATC with negative cooperativity: the
binding of PALA to one subunit decreases the affinity for the inhibitor in the other
active sites (Ruiz-Ramos et al. 2016). Indeed, only two subunits of human ATC
show high affinity for PALA, while affinity for the third site is 100-fold lower. This
difference with the E. coli ATC catalytic trimer, is likely due to a communication of
conformational changes between the subunits in the human enzyme. Since PALA is
proposed to resemble the transition state of the reaction, the negative cooperativity
effect also suggests that in CAD, the ATC trimer might work more efficiently with
only two active sites catalyzing the reaction at a time. Indeed, at high substrate
concentrations, the activity of ATC is partially inhibited, suggesting that a trimer
with the three subunits forced to work simultaneously might present additional
intersubunit interactions that slow down the conformational movements required
for catalysis (LiCata and Allewell 1997; Ruiz-Ramos et al. 2016).
In CAD, ATC catalyzes the reaction *50-fold faster than CPS, and it has a low
KM for CP (Coleman et al. 1977; Qiu and Davidson 2000). This should facilitate
that as soon as the unstable CP molecule is delivered by CPS, it will be trapped and
converted by ATC. A possible asymmetry in the functioning of ATC is interesting
to envision the performance of the overall activity of CAD. Perhaps the ATC
subunits are fired one at a time, in some sequential process coordinated with CPS.
A DHO Domain in the Midst of CAD
DHO is a ubiquitous Zn metalloenzyme catalyzing the reversible interconversion of
carbamoyl aspartate to dihydroorotate –the precursor of the pyrimidine ring– in the
third step of the de novo pyrimidine biosynthesis (Fig. 17.1). Despite full conser-
vation of the reaction, this enzyme adopts an intriguing number of different forms
(Fields et al. 1999; Grande-Garcia et al. 2014). DHOs can be monomeric or dimeric
proteins that function independently (e.g. E. coli DHO) or in association with ATC
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(e.g. A. aeolicus DHO) (Fig. 17.2b, c), or alternatively, DHO can be fused as a
functional domain within CAD (Fig. 17.2a). Moreover, some DHOs seem to play a
non-enzymatic role, such as the inactive DHO-like domain linking the CPS and
ATC activities in the fungal CAD-like proteins (Fig. 17.2a) (Souciet et al. 1989), or
the inactive DHOs that in some bacteria (e.g. Pseudomonas aeruginosa) form
non-covalent complexes with ATC (Schurr et al. 1995). Thus, besides the
well-characterized enzymatic function, DHOs seem to perform other less under-
stood functions in the midst of the pyrimidine enzymatic machinery.
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Although the crystal structures of different bacterial DHOs were known
(Fig. 17.2b, c) (Thoden et al. 2001; Zhang et al. 2009), there were no structures of
any eukaryotic counterpart. The DHO domain of human CAD was the first
eukaryotic DHO for which the crystal structure was solved (Grande-Garcia et al.
2014; Lallous et al. 2012). In agreement with studies reporting that the proteolytic
fragment of CAD retaining DHO activity forms dimers (Davidson et al. 1981), the
isolated human DHO domain was shown to be a homodimer in solution (Fig. 17.8a,
b) (Lallous et al. 2012). The overall subunit fold is similar to bacterial counterparts,
and is also shared with a large number of enzymes –most of which catalyze the
hydrolysis of substrates at amide or ester groups– forming the amidohydrolase
superfamily of proteins (Holm and Sander 1997). Each subunit is structured in a
“TIM” barrel with eight strands of parallel b-sheet flanked on the outer surface by
a-helices, and a smaller adjacent b-stranded subdomain composed of the N- and
C-terminal regions of the protein (Fig. 17.8c). This adjacent subdomain is contin-
ued by a C-terminal extension that stretches through the bottom of the barrel, and
places the N- and C-ends on opposite sides of the globular domain, a convenient
arrangement for the intercalation of DHO in the middle of CAD.
As in other members of the amidohydrolase superfamily, the active center of the
DHO domain of CAD locates on the C-terminal edge of the b-barrel, a cavity
shaped by the loops connecting the b-strands with the outer a-helices (Fig. 17.8c).
There are two Zn2+ ions (Zn-a and Zn-b) coordinated by four His and one Asp at
conserved positions in the active site (Fig. 17.8d). The metals are bridged by the
side chain of a carboxylated Lys and by a water molecule that is activated by the
metal ions for nucleophilic attack (Porter et al. 2004). Human DHO has a third Zn2+
ion (Zn-c) approximately at the center of the b-barrel, which is not found in
bacterial DHOs or in other members of the amidohydrolase superfamily
(Fig. 17.8c, d). This Zn-c interacts with Zn-a through the side chain of a rare
histidine (H1471) with negative charge (called histidinate anion). Although Zn-c
appears to be too far to participate directly in catalysis, mutations that impede the
binding of this metal are shown to reduce the activity of the protein to half
(Grande-Garcia et al. 2014). Interestingly, the introduction by site-directed muta-
genesis of the third Zn2+ into a bacterial DHO, increased the activity and stability of
the protein (Huang and Huang 2015). These results suggest that Zn-c could play a
JFig. 17.8 DHO domain of human CAD. a Space filling representation of the dimer formed by the
isolated DHO domain of human CAD. b Cartoon view of the dimer with two molecules of
dihydroorotate bound at the active sites. c Representation of the DHO subunit with Zn2+ ions and a
dihydroorotate molecule represented as cyan and purples spheres, respectively. d Detail of the
active site with dihydroorotate bound. A molecule of carbamoyl aspartate is shown in
semi-transparent to show that the b-carboxylate occupies the position of the bridging water.
Residues from the central b-barrel and from the loops above the barrel are colored with carbons in
red and grey, respectively. The flexible loop is depicted in yellow. e Cartoon representation of C.
thermophilum inactive DHO-like subunit (e) and dimer (f). The orientations and colors are as in
(b) and (c) to highlight similarities with human DHO
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role in the stabilization of the DHO domain of CAD, and perhaps influence the
electrostatic environment at the active site (Grande-Garcia et al. 2014).
Despite having a low sequence identity (15%), the human and E. coli DHOs
active sites are virtually identical and both enzymes are proposed to share a com-
mon catalytic mechanism (Grande-Garcia et al. 2014; Porter et al. 2004). The
conversion of carbamoyl aspartate to dihydroorotate is reversible and
pH-dependent, with the forward and reverse reactions reaching equilibrium at
approximately neutral pH (Christopherson and Jones 1980). In the synthesis of
dihydroorotate, favored at low pH, the water molecule bridging Zn-a and Zn-b is
displaced by the binding of the side chain of carbamoyl aspartate (Fig. 17.8d). The
metals neutralize the negative charge of the carboxylate group, increasing its sus-
ceptibility to a nucleophilic attack by the amino group of carbamoyl aspartate. To
favor the reaction, the amino group is deprotonated by an Asp (D1686 in human
DHO) acting as the general base. The reaction proceeds by formation of a tetra-
hedral intermediate that becomes stabilized by the metal ions. Then, the OH leaving
group is protonated, collapsing the transition state and releasing dihydroorotate and
a water molecule that is retained between the two metal ions. In turn, the hydrolysis
of dihydroorotate is favored above pH 8 and involves the nucleophilic attack of the
bridging water (or hydroxide ion) to the amide bond of dihydroorotate (Fig. 17.8d).
This reaction, rather than the forward synthesis of dihydroorotate, is favored under
physiological conditions (Christopherson and Jones 1980). It is proposed that the
equilibrium of the reactions could be displaced toward the synthesis of dihy-
droorotate by the location of CAD near the mitochondria, which may facilitate the
efficient capture of dihydroorotate by DHODH, the enzyme catalyzing the next step
in de novo pathway (Evans and Guy 2004) (Fig. 17.1).
The DHO subunit is rigidly built by tight hydrophobic packing of the central
b-barrel and the a-helical palisade. Indeed, different crystal structures of human and
E. coli DHOs show no significant conformational changes upon binding of sub-
strates or different inhibitors at the active site. There is only one exception, a
flexible loop that adopts an open solvent-exposed position or a closed conformation
whether dihydroorotate or carbamoyl aspartate are bound, respectively, to the active
site (del Cano-Ochoa et al. 2018; Grande-Garcia et al. 2014; Lee et al. 2005)
(Fig. 17.8c, d). This loop plays an important catalytic role, placing the substrate in
correct orientation, stabilizing the transition state of the reaction and excluding the
solvent molecules from the active site.
The position of the flexible loops near the dimerization interface of human DHO
suggests a possible coordination between both active sites (Fig. 17.8b). However,
enzymatic assays have failed to detect signs of cooperativity in human DHO (del
Cano-Ochoa et al. 2018; Grande-Garcia et al. 2014). In contrast, in E. coli DHO,
the subunits dimerize through the loops above the b-barrel, rather than by lateral
contacts as in human DHO, and the movements of the flexible loop appear related
to the cooperativity effect observed between the two confronted active sites (Lee
et al. 2005) (Fig. 17.2b). In the A. aeolicus DHO/ATC complex, on the other hand,
526 F. del Caño-Ochoa et al.
the DHO subunits make lateral contacts but the subunits are rotated 180º compared
to human DHO (Fig. 17.2c). As a result, adjacent DHO subunits direct their active
sites towards different ATC trimers. Interestingly, A. aeolicus DHO lacks a catalytic
flexible loop and requires the interaction with a loop from ATC to complete the
active site and achieve maximal activity (Prange et al. 2019; Zhang et al. 2009). It is
intriguing how some DHOs equipped with a flexible loop are catalytically inde-
pendent, whereas others have an unfinished active site that needs to be comple-
mented by a stable association with ATC. Then, we wonder why the DHO domain
of CAD, which has a catalytic flexible loop, is covalently engaged to an ATC
domain that is not necessary for its activity. The answer to this question is that
probably the linkage of both domains is not intended to increase the efficacy of
DHO and must fulfill other purposes. Indeed, the recent crystal structure of the
inactive DHO-like domain from the CAD-like protein of the fungus Chaetomium
thermophilum (Fig. 17.8e) proved that as predicted (Souciet et al. 1989), the cat-
alytic residues and Zn2+ ions are missing from the active site (Moreno-Morcillo
et al. 2017). However, this inactive domain forms homodimers in an identical
quaternary arrangement as human DHO (Fig. 17.8f). The preservation of the dimer
architecture strongly suggests that the DHO domain plays a conserved structural
role within the context of the full-length protein oligomerization. The linkage with
ATC must harness both domains for the assembly of a multienzymatic protein
machinery that appears conserved both in animals and fungi (Moreno-Morcillo
et al. 2017).
Putting the Pieces Together for the Pyrimidine Factory
Based on the expected similarity of the GLN and SYN domains of CAD with
E. coli CPS and human CPS-1 and on the crystal structures of the human DHO and
ATC structures, we can build a hypothetical model of the full-length protein with
the four domains arranged as beads on a string (Fig. 17.9a). However, this model is
utterly useless unless we define how this protein self-assembles into larger particles
that explain the communication and coordination between the different activities.
Early studies reported that CAD self-assembles into a mixture of oligomers
(Coleman et al. 1977), mostly hexamers of *1.5 MDa in size (Lee et al. 1985).
Since the proteolytic fragments retaining DHO and ATC activities were found to
form dimers and trimers, respectively (Davidson et al. 1981; Hemmens and Carrey
1994; Kelly et al. 1986), an idea prevailed, that the CAD hexamers could result
from the association of three proteins through their respective ATC domains, and
that two of these trimers could further dimerize through their DHO domains (Carrey
1995b; Evans 1986). A similar organization was proposed for the architecture of the
CAD-like protein in Neurospora (Makoff et al. 1978), although in this model the
dimerization of the trimers was proposed to be mediated by the CPS region.
The key role of ATC in the molecular organization of CAD was demonstrated by
Qiu and Davidson, who proved that mutations in the predicted ATC trimer interface
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caused the dissociation of CAD hexamers (Qiu and Davidson 1998, 2000).
However, this study ruled out the possibility that the DHO or CPS domains par-
ticipated directly in the oligomerization of the particle.
To challenge the idea proposed by Carrey that CAD could assemble as a “dimer
of trimers” (Carrey 1995b), our group made a construct spanning the DHO and
ATC domains of human CAD, including the long linker in between. This
bi-functional construct was shown to form stable homo-hexamers in solution, and
point mutations in the ATC or DHO oligomerization interfaces resulted in the
formation of dimers and trimers, respectively (Moreno-Morcillo et al. 2017). These
results indicate that CAD indeed assembles as a “dimer of trimers” and suggest that
the DHO and ATC domains provide a central scaffold for the architecture of the
particle (Fig. 17.9b). Moreover, we proved that despite having an inactive
DHO-like domain, a similar construct from the CAD-like protein from C. ther-
mophilum behaves in the same manner, supporting that CAD and CAD-like par-
ticles share a common architecture (Moreno-Morcillo et al. 2017).
Taking into consideration previous models (Carrey 1995b; Evans 1986; Makoff
et al. 1978) and gathering all the current structural information, we propose a
plausible blueprint for the architecture of CAD (Fig. 17.9c, d). The DHO and ATC
domains form the central axis of the particle. The ATC monomers are arranged into
two trimers occupying apical positions and with the active sites face-to-face.
Three DHO dimers interpose in between the ATC trimers, with their long axes in
parallel to the threefold axis of the ATC domains and with the active sites facing
inwards. This results in a closed hexameric structure of 190  100 Å, with D3
symmetry (a threefold axis with three perpendicular twofold axes) and a delimited
inner space of *120  50 Å (Moreno-Morcillo et al. 2017; Moreno-Morcillo and
Ramon-Maiques 2017). This disposition of the ATC and DHO domains is some-
how reminiscent of the noncovalent association between the regulatory and cat-
alytic subunits of E. coli ATC or between the ATC and DHO enzymes of A.
aeolicus (Fig. 17.2b, c).
Negative staining electron microscopy data indicated that the hexamer formed
by the DHO-ATC construct is quite flexible (Moreno-Morcillo et al. 2017). The
long sequence connecting the DHO and ATC domains likely restrains the relative
position of both domains, but allows certain flexibility between them. Perhaps the
DHO dimers could tilt around their twofold axes, allowing the separation or
approximation of the ATC trimers, into tighter or more relaxed states that limit the
conformational changes required for catalysis, in a similar manner to the allosteric
transitions described in the E. coli ATC holoenzyme (Fig. 17.2b) (Lipscomb 1994;
Lipscomb and Kantrowitz 2011; Ruiz-Ramos et al. 2016).
JFig. 17.9 Model of the architecture of CAD. a Model of CAD full-length protein with the GLN,
SYN, DHO and ATC domains as beads on a string. Dashed lines indicate linker regions of
different lengths. b Model of the bi-functional DHO-ATC construct forming an hexamer (or
“dimer of trimers”). c, d Hypothetical model of CAD hexameric particle in two perpendicular
orientations
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Some regions of the long linker connecting DHO and ATC could make inter-
actions with both domains, and also perhaps with the GLN/SYN domains, adding
stability to the assembly. However, a part of the linker must be exposed to the
solvent to explain the high sensitivity to proteases and also, for being phosphory-
lated. Two different studies reported that residue S1859 at the linker sequence in
human CAD is phosphorylated by S6 kinase in the downstream of mTORC1
pathway, and that this modification increases the rate of de novo pyrimidine syn-
thesis (Ben-Sahra et al. 2013; Robitaille et al. 2013). Interestingly, the phospho-
rylation also favors the oligomerization of CAD (Robitaille et al. 2013), in
agreement with a possible role of the linker in the stabilization of the particle.
To complete the model, six CPS-2, formed by the GLN and SYN domains, need
to be added to the central DHO-ATC framework. It is clear by similarity to other
CPSs and by biochemical data that the GLN and SYN domains will form a tight
heterodimer. Also, the observation that proteolytic fragments of Neurospora
CAD-like protein with CPS activity form dimers (Makoff et al. 1978), suggests that
CPS-2 could further dimerize through the allosteric regions, similarly to the dimers
observed in the crystal structures of E. coli CPS and human CPS-1 (Figs. 17.3c and
17.4b). We propose that the six CPS-2 could be organized as three dimers sur-
rounding the central DHO-ATC assembly, with the twofold axes in the equatorial
plane of this globular complex of *200  200 Å (Fig. 17.9c, d).
Despite the symmetrical beauty, this model could be wrong and needs more
structural data to be validated. A detailed characterization of the particle, probably
by using high resolution cryo-microscopy, will shed light on the evolutionary
advantages of a single multienzymatic protein versus the mono-functional homo-
logs in prokaryotes. Till then, it can only be hypothesized that the engineering of
several enzymatic activities into a single polypeptide likely improves the metabolic
efficiency in a number of ways (Davidson et al. 1993; Stark 1977). Firstly, similar
to a bacterial operon, the fusion of the enzymes into a single polypeptide ensures
the coordinated and stoichiometric production of the enzymatic activities. In
addition, the covalent linkage favors the co-localization of the different activities
within the cell. The proximity between domains might also enhance the specificity
for their association, and this could also result in increased stability compared to the
isolated proteins. Another advantage for the formation of a complex such as the one
proposed in Fig. 17.9, is the close proximity between active sites, which should
favor the transfer or “channeling” of intermediate metabolites. The concept of
channeling was introduced by Davis to explain the existence of two different pools
of CP in the cell for the de novo biosynthesis of pyrimidines and arginine (Davis
1972). The fact that in de novo pyrimidine synthesis there is no significant accu-
mulation of any of the intermediates between bicarbonate and UMP, led M.
E. Jones to consider that the enzymes could have a special structural conformation
that ensures products and substrates to reach their destination (Jones 1971, 1980;
Shoaf and Jones 1971). The proposed model accounts for the partial channeling of
CP reported by different studies in mammalian CAD and in the CAD-like from
yeast (Christopherson and Jones 1980; Mally et al. 1980; Otsuki et al. 1982;
Penverne et al. 1994). Channeling starts at the GLN domain following the *90 Å
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tunnel running through the interior of the SYN domain. The orientation of the
CPS-2 dimers in the particle would be such that the exit of this intramolecular
tunnel could face the gaps between the DHO dimers. In this manner, the CP would
be delivered from the SYN domains directly into the central cavity of the particle
where it would diffuse a short distance to reach the ATC active site without
exposure to the bulk solvent.
This large multi-subunit and multi-domain assembly might also allow for a more
complex mechanism of control. It is possible that binding of the allosteric effectors,
UTP and PRPP, at the regulatory domains could induce conformational changes as
those observed in CPS-1 upon acetylglutamate binding (de Cima et al. 2015).
Changes in the relative orientation of the CPS-2 dimer could be transmitted to the
rest of the protein, inducing the rotation and translation of the DHO dimers and
ATC trimers along their respective symmetry axes, and reversely, conformational
changes in the ATC trimer due to substrate or PALA binding, could be commu-
nicated to the outer CPS-2 dimers. This conformational cross-talk would explain the
mutual effects between both enzymatic activities that E. Carrey described as “re-
ciprocal allostery” (Irvine et al. 1997). The concerted movements of the domains
could modulate the affinity for the substrates, the rate and the coupling of the
reactions, the channeling of intermediates as well as the flux of substrates and
products in and out the particle. In a stretch of imagination, one can envision that
the hexameric particle could transit through a series of conformational states with
different overall activity, and that a number of external inputs such as allosteric
effectors, phosphorylations and other posttranslational modifications or interactions
with other cellular components could displace the conformational equilibrium, thus
contributing to the regulation of the de novo pyrimidine pathway.
CAD in Human Diseases
Whereas a complete lack of activity in any of the enzymatic activities for de novo
biosynthesis of pyrimidines appears to be incompatible with life, mutations causing
impairment of the activities associate with different human disorders. Defects in
DHODH activity are associated with Miller syndrome, a malformation disorder
with no intellectual damage (Ng et al. 2010). Also, UMPS malfunctions cause
orotic aciduria, a condition in which the accumulation of orotate produces intel-
lectual and motor impairment, seizures and immunodeficiency (Imaeda et al. 1998;
Loffler et al. 2015). However, until recently, no human disease had been related to a
partial loss of CAD activity. Mutations compromising CAD function were known
to cause severe malformations and death in model organisms such as Drosophila
(rudimentary phenotype) (Norby 1970), zebrafish (perplexed phenotype) (Willer
et al. 2005) and C. elegans (Franks et al. 2006). These results led to the assumption
that a reduced function of CAD would be lethal and explained that no human
diseases were associated with failures in this protein.
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However, in 2015, H. Freeze and colleagues described the first case of a 4-year
old boy with a severe impairment of protein glycosylation caused by a partial deficit
in CAD (Ng et al. 2015). The identified mutation, R2024Q, maps in the active site
of ATC, and it was shown to severely reduce the activity of the isolated ATC
domain and its affinity for the substrates (Ruiz-Ramos et al. 2016). One year later, a
second study reported three families with young children carrying mutations in
CAD that caused developmental delay, epileptic encephalopathy, anemia and sei-
zures (Koch et al. 2017). While the untreated disease course is lethal in early
childhood, both studies reported that patients survived upon an oral treatment with
uridine, which compensates by salvage the defects of the de novo pyrimidine
synthesis. Since then, new cases of children with potential CAD-deficits have
continued appearing (H. Freeze personal communication).
The identification of CAD-deficiency as a treatable metabolic disorder stresses
the importance of an early detection in newborns and young children (Koch et al.
2017). However, the diagnosis is difficult (e.g. numerous symptoms, pyrimidine
levels in urine might seem normal) and so far, patients were only diagnosed after
complete exome sequencing (Koch et al. 2017; Ng et al. 2015). As these
sequencing techniques become more affordable, a major challenge that remains,
giving our fragmented knowledge about CAD, is the distinction between
disease-causing mutations and simple protein polymorphisms. Thus, deciphering
the architecture of CAD is not only key to unveil the catalytic and regulatory
mechanisms of a central metabolic machinery and to guide in the design of specific
inhibitors with a potential chemotherapeutic use, but also is of paramount impor-
tance for helping in the correct diagnosis and treatment of patients.
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